Ajay K Gopal

Ajay K Gopal

UNVERIFIED PROFILE

Are you Ajay K Gopal?   Register this Author

Register author
Ajay K Gopal

Ajay K Gopal

Publications by authors named "Ajay K Gopal"

Are you Ajay K Gopal?   Register this Author

100Publications

2369Reads

50Profile Views

Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma.

Clin Cancer Res 2019 Sep 3. Epub 2019 Sep 3.

Department of Medicine, University of Washington School of Medicine, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-1567DOI Listing
September 2019

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.

Clin Lymphoma Myeloma Leuk 2019 Jun 11;19(6):390-395. Epub 2019 Mar 11.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.03.003DOI Listing
June 2019

Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.

Clin Lymphoma Myeloma Leuk 2019 May 2;19(5):275-284. Epub 2019 Jan 2.

Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183128
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.12.013DOI Listing
May 2019

Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.

Am J Hematol 2019 Apr 4;94(4):E117-E116. Epub 2019 Feb 4.

Department of Medicine, Division of Medical Oncology, University of Washington Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25411DOI Listing
April 2019

Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal.

Biol Blood Marrow Transplant 2019 03 26;25(3):570-576. Epub 2018 Oct 26.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington; Division of Nephrology, Seattle Children's Hospital, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.10.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450411PMC
March 2019

Long-Term Follow-Up of Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma.

Biol Blood Marrow Transplant 2018 11 3;24(11):2211-2215. Epub 2018 Jul 3.

Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183038
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.06.033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251312PMC
November 2018

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.

J Clin Oncol 2018 08 31;36(23):2405-2412. Epub 2018 May 31.

Ajay K. Gopal, The University of Washington; Ajay K. Gopal, Fred Hutchinson Cancer Research Center, Seattle, WA; Stephen J. Schuster, Abramson Cancer Center of the University of Pennsylvania, Philadelphia; Jing-Zhou Hou, University of Pittsburgh Medical Center; Jing-Zhou Hou, University of Pittsburgh Cancer Institute, Pittsburgh; Rajendra N. Damle, Michael Schaffer, and Sriram Balasubramanian, Janssen Research & Development, Spring House, PA; Nathan H. Fowler, The University of Texas MD Anderson Cancer Center, Houston, TX; Judith Trotman, Concord Hospital, University of Sydney, Sydney, New South Wales; Andrew Spencer, Alfred Hospital-Monash University, Melbourne, Victoria; James Morton, Haematology and Oncology Clinics of Australia, Milton, Queensland, Australia; Georg Hess, Johannes Gutenberg-University, Mainz, Germany; Abdulraheem Yacoub, Kansas University Medical Center, Kansas City, KS; Michael Lill, Cedars-Sinai Medical Center, Los Angeles, CA; Peter Martin, Weill Cornell Medical College, Cornell University, New York, NY; Umberto Vitolo, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy; John Radford, University of Manchester; John Radford, Christie National Health Service Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; Wojciech Jurczak, Jagiellonian University, Kraków, Poland; Dolores Caballero, Hospital Clínico Universitario, Salamanca, Spain; Sanjay Deshpande, Gary J. Gartenberg, and Shean-Sheng Wang, Janssen Research & Development, Raritan, NJ; Jessica Vermeulen, Janssen Research & Development, Leiden, the Netherlands; Bruce D. Cheson, Georgetown University Hospital, Washington, DC; and Gilles Salles, Hospices Civils de Lyon-Université de Lyon, Pierre-Bénite cedex, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.8853DOI Listing
August 2018

Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.

Blood 2018 08 18;132(8):777-781. Epub 2018 Jun 18.

Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-04-839217DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6107879PMC
August 2018

Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.

Biol Blood Marrow Transplant 2018 07 1;24(7):1386-1391. Epub 2018 Mar 1.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington; Seattle Cancer Care Alliance, Seattle, Washington. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183010
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.02.017DOI Listing
July 2018

Have we found the right patient population for transplantation in follicular lymphoma?

Cancer 2018 06 12;124(12):2484-2487. Epub 2018 Apr 12.

Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31376DOI Listing
June 2018

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.

Clin Cancer Res 2018 04 16;24(8):1816-1823. Epub 2018 Mar 16.

University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, Washington.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-17-1922DOI Listing
April 2018

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

J Clin Oncol 2018 03 22;36(7):697-703. Epub 2018 Jan 22.

Mazyar Shadman, Ajay K. Gopal, David G. Maloney, and Oliver W. Press, University of Washington and Fred Hutchinson Cancer Research Center; Hongli Li and Michael LeBlanc, SWOG Statistical Center, Seattle, WA; Lisa Rimsza, Mayo Clinic Arizona, Scottsdale; Catherine M. Spier, University of Arizona, Tucson, AZ; John P. Leonard, Weill Cornell Medical College, New York; Jonathan W. Friedberg, Wilmot Cancer Institute, University of Rochester, Rochester, NY; Mark S. Kaminski, University of Michigan Health System, Ann Arbor, MI; Rita M. Braziel, Oregon Health & Science University, Portland, OR; Bruce D. Cheson, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC; Shaker Dakhil, University of Kansas School of Medicine-Wichita, Wichita, KS; Sonali M. Smith, University of Chicago Medicine, Chicago, IL; and Richard I. Fisher, Fox Chase Cancer Center and Temple University School of Medicine, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.5083
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.5083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553811PMC
March 2018

Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.

Biol Blood Marrow Transplant 2018 02 20;24(2):282-287. Epub 2017 Oct 20.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791173079
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2017.10.029DOI Listing
February 2018

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

Blood 2017 06 21;129(22):3037-3039. Epub 2017 Mar 21.

Department of Medicine, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-12-757740DOI Listing
June 2017

Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications.

Exp Hematol 2017 05 21;49:34-38.e2. Epub 2017 Jan 21.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2017.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393923PMC
May 2017

Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.

Clin Lymphoma Myeloma Leuk 2017 04 10;17(4):225-230. Epub 2017 Jan 10.

Seattle Cancer Care Alliance, Seattle, WA; Department of Medicine, University of Washington School of Medicine, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650163064
Publisher Site
http://dx.doi.org/10.1016/j.clml.2016.12.004DOI Listing
April 2017

Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.

Pharmaceuticals (Basel) 2017 Mar 10;10(1). Epub 2017 Mar 10.

Department of Medicine, University of Washington, Seattle, WA 98195, USA.

View Article

Download full-text PDF

Source
http://www.mdpi.com/1424-8247/10/1/28
Publisher Site
http://dx.doi.org/10.3390/ph10010028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374432PMC
March 2017

Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review.

Case Rep Hematol 2017 21;2017:2676254. Epub 2017 Feb 21.

Department of Medicine, University of Washington School of Medicine, P.O. Box 356420, 1959 NE Pacific Street, Seattle, WA 98195, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/2676254DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339518PMC
February 2017

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

J Natl Cancer Inst 2017 01 31;109(1). Epub 2016 Dec 31.

Affiliations of authors: Division of Hematology and Medical Oncology, Oregon Health and Science (OHSU) University Knight Cancer Institute, Portland, OR (SES); Clinical Research Division, Fred Hutchinson Cancer Research Center/ Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA (BGT, AKG); Department of Medicine, Weill Cornell Medicine, New York, NY (PM, JPL); John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ (AHG); Department of Medicine III, Klinikum der Universität München, Campus Grosshadern, Munich, Germany (MPD); Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA (ML); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Coordinating Center for Clinical Trials, National Cancer Institute, National Institutes of Health, Bethesda, MD (LB); HIV and AIDS Malignancy Branch, Center for Cancer Research, and Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD (RFL); Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH (MRS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059122PMC
January 2017

Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.

Biol Blood Marrow Transplant 2016 09 14;22(9):1582-1587. Epub 2016 Jun 14.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.06.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981519PMC
September 2016

Idelalisib for the treatment of non-Hodgkin lymphoma.

Expert Opin Pharmacother 2016 28;17(2):265-74. Epub 2016 Jan 28.

a Department of Medicine, University of Washington, Seattle , WA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2016.1135130DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955805PMC
June 2016

Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.

Cancer Immunol Res 2016 06 21;4(6):509-19. Epub 2016 Apr 21.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Division of Medical Oncology, University of Washington School of Medicine, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0276DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891234PMC
June 2016

What is the role of transplantation for indolent lymphoma?

Am Soc Clin Oncol Educ Book 2012 :494-500

From the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.494DOI Listing
April 2016

Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.

PLoS One 2015 18;10(3):e0120561. Epub 2015 Mar 18.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Departments of Medicine and Bioengineering, University of Washington, Seattle, WA, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0120561PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364776PMC
February 2016

New targeted therapies for indolent B-cell malignancies in older patients.

Am Soc Clin Oncol Educ Book 2015 :e365-74

From the University of Louisville Brown Cancer Center, Louisville, KY; Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e365DOI Listing
February 2016

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Blood 2016 Jan 17;127(3):352-9. Epub 2015 Nov 17.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA; and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-12-617019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722286PMC
January 2016

Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.

Anticancer Drugs 2015 Oct;26(9):974-83

aClinical Research Division, Fred Hutchinson Cancer Research Center bDepartment of Medicine, Division of Medical Oncology, University of Washington cSeattle Genetics Inc., Seattle, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000274DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545689PMC
October 2015

Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.

PLoS One 2014 2;9(12):e113601. Epub 2014 Dec 2.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America; Medical Oncology, University of Washington, Seattle, WA, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0113601PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4252056PMC
July 2015

A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

Clin Lymphoma Myeloma Leuk 2015 Jul 5;15(7):392-7. Epub 2015 Mar 5.

Department of Medicine, University of Washington School of Medicine, and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650150006
Publisher Site
http://dx.doi.org/10.1016/j.clml.2015.02.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484300PMC
July 2015

Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.

Biol Blood Marrow Transplant 2015 Feb 1;21(2):281-7. Epub 2014 Nov 1.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Medicine, University of Washington, Seattle, Washington. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.10.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408880PMC
February 2015

Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.

Br J Haematol 2015 Jan 22;168(1):38-45. Epub 2014 Aug 22.

Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.13099
Publisher Site
http://dx.doi.org/10.1111/bjh.13099DOI Listing
January 2015

Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.

Hematology Am Soc Hematol Educ Program 2014 Dec 18;2014(1):151-7. Epub 2014 Nov 18.

Department of Medicine and Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2014.1.151DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418463PMC
December 2014

90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution.

Nucl Med Commun 2014 Nov;35(11):1132-42

Departments of aRadiology bMedicine, Division of Medical Oncology, University of Washington Medical Center cClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington dDepartment of Radiology, Harvard Medical School, MGH Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0000000000000172DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169733PMC
November 2014

Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.

Biol Blood Marrow Transplant 2014 Jun 12;20(6):770-5. Epub 2014 Feb 12.

Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.02.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019701PMC
June 2014

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

Cancer Res 2014 Feb 26;74(4):1179-89. Epub 2013 Dec 26.

Authors' Affiliations: Clinical Research Division, Fred Hutchinson Cancer Research Center; Departments of Medicine, Radiation Oncology, and Laboratory Medicine, University of Washington, Seattle; and Dade Moeller Health Group, Richland, Washington.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/content/74/4/1179.full.pdf
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-13-1589DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970848PMC
February 2014

A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

Clin Cancer Res 2013 Dec 15;19(23):6624-32. Epub 2013 Oct 15.

Authors' Affiliations: Clinical Research Division; SWOG Statistical Center, Fred Hutchinson Cancer Research Center; Medical Oncology, University of Washington Medical Center, Seattle, Washington; Department of Pathology; Arizona Cancer Center, University of Arizona, Tucson, Arizona; James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester; Roswell Park Cancer Institute, Buffalo, New York; Cancer and Leukemia Group B; University of Michigan, Ann Arbor, Michigan; Department of Pathology, Oregon Health and Science University, Portland, Oregon; Georgetown University Hospital, Washington; Wichita Community Clinical Oncology Program, Wichita, Kansas; and Fox Chase Cancer Center-Temple Health, Temple University, Philadelphia PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1120DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872052PMC
December 2013

131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.

Nucl Med Commun 2012 Dec;33(12):1225-31

aDepartment of Radiology, Division of Nuclear Medicine, University of Washington bFred Hutchinson Cancer Research Center, Seattle cPacific Northwest National Laboratory, Richland, Washington, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0b013e328358d34bDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703155PMC
December 2012

The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.

J Clin Apher 2012 2;27(2):81-7. Epub 2012 Feb 2.

Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington 98195, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jca.21206
Publisher Site
http://dx.doi.org/10.1002/jca.21206DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004340PMC
August 2012

Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms.

Clin Lymphoma Myeloma Leuk 2012 Aug 26;12(4):280-3. Epub 2012 Apr 26.

Department of Laboratory Medicine, University of Washington, Seattle, Washington 98195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2012.01.012DOI Listing
August 2012

Allogeneic hematopoietic cell transplantation in mantle cell lymphoma.

Best Pract Res Clin Haematol 2012 Jun 3;25(2):165-74. Epub 2012 May 3.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2012.04.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3374153PMC
June 2012

Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation.

Korean J Hematol 2012 Mar 28;47(1):8-16. Epub 2012 Mar 28.

Department of Internal Medicine, University of Washington School of Medicine, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5045/kjh.2012.47.1.8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317478PMC
March 2012

Relapsed mantle cell lymphoma presenting as "sister Mary joseph nodule".

Case Rep Med 2010 8;2010:708348. Epub 2010 Apr 8.

Department of Internal Medicine, University of Washington, Box 39892. 325 Ninth Ave., Seattle, WA 98104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2010/708348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852603PMC
July 2011

Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation.

Curr Opin Oncol 2010 Mar;22(2):143-9

Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine from the University of Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00001622-201003000-000
Publisher Site
http://dx.doi.org/10.1097/CCO.0b013e328335ccc2DOI Listing
March 2010